Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874237 · ClinicalTrials.gov registry record · Phase 1
Staccato Loxapine Thorough QT/QTc Study
A Phase 1 study of Thorough QT/QTc Study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00874237 is a Phase 1 study of Thorough QT/QTc Study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00874237, a Phase 1 study of Thorough QT/QTc Study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.
Conditions Studied
Interventions
- DRUG Oral placebo
- DRUG Inhaled loxapine
- DRUG Inhaled placebo
- DRUG Oral moxifloxacin
Study Locations (1)
Indiana
- Covance Clinical Research Unit Inc. - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874237
The ClinicalTrials.gov registry entry for NCT00874237 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thorough QT/QTc Study appearing as the primary indexed condition, and to 4 interventions - of which Oral placebo is the first listed.
NCT00874237 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00874237 about?
NCT00874237 is a clinical study titled "Staccato Loxapine Thorough QT/QTc Study". The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.
What is the current status of trial NCT00874237?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2009-04. Estimated completion is 2009-06.
What conditions does trial NCT00874237 study?
This clinical trial studies the following conditions: Thorough QT/QTc Study.
What interventions are being tested in trial NCT00874237?
The interventions under investigation include: Oral placebo (DRUG), Inhaled loxapine (DRUG), Inhaled placebo (DRUG), Oral moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT00874237?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00874237 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.